{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:41:35Z","timestamp":1791312095752,"version":"4.3.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009898","name":"Defense Health Agency","doi-asserted-by":"publisher","award":["W81XWH-16-PCRP-IDA"],"award-info":[{"award-number":["W81XWH-16-PCRP-IDA"]}],"id":[{"id":"10.13039\/100009898","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["R21CA2022552"],"award-info":[{"award-number":["R21CA2022552"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institutes of Minority Health & Health Disparities","award":["1R01MD007105-01"],"award-info":[{"award-number":["1R01MD007105-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Predictive models that take race into account like the Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPT RC) and the new Prostate Biopsy Collaborative Group (PBCG) RC have been developed to equitably mitigate the overdiagnosis of prostate specific antigen (PSA) screening. Few studies have compared the performance of both calculators across racial groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From 1485 prospectively recruited participants, 954 men were identified undergoing initial prostate biopsy for abnormal PSA or digital rectal examination in five Chicago hospitals between 2009 and 2014. Discrimination, calibration, and frequency of avoided biopsies were calculated to assess the performance of both risk calculators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 954 participants, 463 (48.5%) were Black, 355 (37.2%) were White, and 136 (14.2%) identified as Other. Biopsy results were as follows: 310 (32.5%) exhibited no cancer, 323 (33.9%) indolent prostate cancer, and 321 (33.6%) clinically significant prostate cancer (csPCa). Differences in area under the curve (AUC)s for the detection of csPCa between PCPT and PBCG were not statistically different across all racial groups. PBCG did not improve calibration plots in Blacks and Others, as it showed higher levels of overprediction at most risk thresholds. PCPT led to an increased number of avoidable biopsies in minorities compared to PBCG at the 30% threshold (68% vs. 28% of all patients) with roughly similar rates of missed csPCa (23% vs. 20%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Significant improvements were noticed in PBCG\u2019s calibrations and net benefits in Whites compared to PCPT. Since PBCG\u2019s improvements in Blacks are disputable and potentially biases a greater number of low risk Black and Other men towards unnecessary biopsies, PCPT may lead to better biopsy decisions in racial minority groups. Further comparisons of commonly used risk calculators across racial groups is warranted to minimize excessive biopsies and overdiagnosis in ethnic minorities.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12894-019-0553-6","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T02:02:32Z","timestamp":1574820152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort"],"prefix":"10.1186","volume":"19","author":[{"given":"Samuel","family":"Carbunaru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwarotimi S.","family":"Nettey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Gogana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene B.","family":"Helenowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borko","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ruden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney M. P.","family":"Hollowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roohollah","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick A.","family":"Kittles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"key":"553_CR1","unstructured":"Key Statistics for Prostate Cancer Date. Available from: https:\/\/www.cancer.org\/cancer\/prostate-cancer\/about\/key-statistics.html2019. Accessed 3 Jan 2019."},{"issue":"2","key":"553_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.eururo.2013.08.005","volume":"65","author":"LP Bokhorst","year":"2014","unstructured":"Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schr\u00f6der FH, et al. Prostate-specific antigen\u2013based prostate Cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European randomized study of screening for prostate Cancer. Eur Urol. 2014;65(2):329\u201336.","journal-title":"Eur Urol"},{"issue":"5","key":"553_CR3","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.juro.2011.06.057","volume":"186","author":"S Loeb","year":"2011","unstructured":"Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186(5):1830\u20134.","journal-title":"J Urol"},{"issue":"4","key":"553_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.2014.17942","volume":"313","author":"MM Siddiqui","year":"2015","unstructured":"Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR\/ultrasound fusion\u2013guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390\u20137.","journal-title":"JAMA"},{"issue":"2","key":"553_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.juro.2017.01.103","volume":"198","author":"MA Liss","year":"2017","unstructured":"Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, et al. An update of the American urological association white paper on the prevention and treatment of the more common complications related to prostate biopsy. J Urol. 2017;198(2):329\u201334.","journal-title":"J Urol"},{"issue":"1","key":"553_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1001\/jamaoncol.2014.161","volume":"1","author":"C Zeng","year":"2015","unstructured":"Zeng C, Wen W, Morgans AK, Pao W, Shu X-O, Zheng W. Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute surveillance, epidemiology, and end results (SEER) program in the United States, 1990 to 2010. JAMA Oncol. 2015;1(1):88\u201396.","journal-title":"JAMA Oncol"},{"issue":"2","key":"553_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","volume":"157","author":"VA Moyer","year":"2012","unstructured":"Moyer VA. Screening for prostate cancer: US preventive services task force recommendation statement. Ann Intern Med. 2012;157(2):120\u201334.","journal-title":"Ann Intern Med"},{"issue":"18","key":"553_CR8","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/jnci\/djp262","volume":"101","author":"Y-H Shao","year":"2009","unstructured":"Shao Y-H, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009;101(18):1280\u20133.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"553_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2018.05.003","volume":"74","author":"DP Ankerst","year":"2018","unstructured":"Ankerst DP, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, et al. A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. Eur Urol. 2018;74(2):197\u2013203.","journal-title":"Eur Urol"},{"issue":"6","key":"553_CR10","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","volume":"83","author":"DP Ankerst","year":"2014","unstructured":"Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, et al. Prostate Cancer prevention trial risk calculator 2.0 for the prediction of low-vs high-grade prostate cancer. Urology. 2014;83(6):1362\u20138.","journal-title":"Urology"},{"issue":"5","key":"553_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/1557988312437240","volume":"6","author":"AB Murphy","year":"2012","unstructured":"Murphy AB, Kelley B, Nyame YA, Martin IK, Smith DJ, Castaneda L, et al. Predictors of serum vitamin D levels in African American and European American men in Chicago. Am J Mens Health. 2012;6(5):420\u20136.","journal-title":"Am J Mens Health"},{"issue":"5","key":"553_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ, D\u2019Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(5):479\u2013505.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"553_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. J Med Decis Making. 2006;26(6):565\u201374.","journal-title":"J Med Decis Making"},{"issue":"3","key":"553_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bju.13913","volume":"120","author":"PK Chiu","year":"2017","unstructured":"Chiu PK, Alberts AR, Venderbos LD, Bangma CH, Roobol MJ. Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European randomized study of screening for prostate Cancer. BJU Int. 2017;120(3):394\u2013400.","journal-title":"BJU Int"},{"issue":"5","key":"553_CR15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamaoncol.2017.5667","volume":"4","author":"S Mehralivand","year":"2018","unstructured":"Mehralivand S, Shih JH, Rais-Bahrami S, Oto A, Bednarova S, Nix JW, et al. A magnetic resonance imaging\u2013based prediction model for prostate biopsy risk stratification. JAMA Oncol. 2018;4(5):678\u201385.","journal-title":"JAMA Oncol"},{"key":"553_CR16","doi-asserted-by":"publisher","first-page":"i6","DOI":"10.1136\/bmj.i6","volume":"352","author":"AJ Vickers","year":"2016","unstructured":"Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ. 2016;352:i6.","journal-title":"BMJ"},{"issue":"1","key":"553_CR17","first-page":"45","volume":"72","author":"MJ Roobol","year":"2017","unstructured":"Roobol MJ, Verbeek JF, van der Kwast T, K\u00fcmmerlin IP, Kweldam CF, van Leenders GJ. Improving the Rotterdam European randomized study of screening for prostate Cancer risk calculator for initial prostate biopsy by incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. J Eur Oncol. 2017;72(1):45\u201351.","journal-title":"J Eur Oncol"},{"issue":"4","key":"553_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1198\/000313008X370302","volume":"62","author":"AJ Vickers","year":"2008","unstructured":"Vickers AJ. Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat. 2008;62(4):314\u201320.","journal-title":"Am Stat"},{"issue":"2","key":"553_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00345-011-0818-5","volume":"30","author":"DP Ankerst","year":"2012","unstructured":"Ankerst DP, Boeck A, Freedland SJ, Thompson IM, Cronin AM, Roobol MJ, et al. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the prostate biopsy collaborative group. World J Urol. 2012;30(2):181\u20137.","journal-title":"World J Urol"},{"issue":"6","key":"553_CR20","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.urology.2006.10.022","volume":"68","author":"DJ Parekh","year":"2006","unstructured":"Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T, et al. External validation of the prostate Cancer prevention trial risk calculator in a screened population. Urology. 2006;68(6):1152\u20135.","journal-title":"Urology"},{"issue":"2","key":"553_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.eururo.2018.07.031","volume":"75","author":"AR Alberts","year":"2019","unstructured":"Alberts AR, Roobol MJ, Verbeek JF, Schoots IG, Chiu PK, Osses DF, et al. Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam european randomized study of screening for prostate cancer risk calculators. Eur Urol. 2019;75(2):310\u20138.","journal-title":"Eur Urol"},{"issue":"12","key":"553_CR22","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2018.4160","volume":"4","author":"SJ Kim","year":"2018","unstructured":"Kim SJ, Vickers AJ, Hu JC. Challenges in adopting level 1 evidence for multiparametric magnetic resonance imaging as a biomarker for prostate cancer screening. JAMA Oncol. 2018;4(12):1663\u20134.","journal-title":"JAMA Oncol"},{"key":"553_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.urology.2018.04.007","volume":"117","author":"W Liu","year":"2018","unstructured":"Liu W, Patil D, Howard DH, Moore RH, Wang H, Sanda MG, et al. Adoption of prebiopsy magnetic resonance imaging for men undergoing prostate biopsy in the United States. Urology. 2018;117:57\u201363.","journal-title":"Urology"},{"issue":"6","key":"553_CR24","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s00330-016-4635-5","volume":"27","author":"NL Hansen","year":"2017","unstructured":"Hansen NL, Koo BC, Gallagher FA, Warren AY, Doble A, Gnanapragasam V, et al. Comparison of initial and tertiary Centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy. Eur Radiol. 2017;27(6):2259\u201366.","journal-title":"Eur Radiol"},{"issue":"2","key":"553_CR25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2016;40(2):244\u201352.","journal-title":"Am J Surg Pathol"},{"key":"553_CR26","unstructured":"Prostate Cancer Prevention Trial Risk Calculator Version 2.0. Available from: http:\/\/riskcalc.org\/PCPTRC\/."}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-019-0553-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-019-0553-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-019-0553-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T19:47:45Z","timestamp":1612640865000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-019-0553-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1186\/s12894-019-0553-6","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,27]]},"assertion":[{"value":"10 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Data was obtained from our prospectively maintained and institutional review board-approved dataset at Northwestern University (STU00005398). The participants were also recruited after institutional review board-approval at University of Chicago (16811B), Jesse Brown VA Medical Center (5R01MD007105\u201303), Cook County Health (08\u2013174) and University of Illinois at Chicago (2010-0951). Written informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}